Quote:

---

Does anyone know?...what the Placebo numbers were compared to Leronlimab...given the difference between Trodolvey and Leronlimab as reported was seemingly minimal.

---

We'll find out. That the placebo arm was only carboplatin the numbers would be much better than the comparison to Trodelvy. The minimal difference was because after 12+ months the mOS hadn't even occurred yet. It could be much more significant which is why I'm impatiently waiting for the peer reviewed paper. A 25% increase over Trodelvy wouldn't surprise me.

My memory must be slipping. When I went to make sure it was only carboplatin in the placebo arm I saw I'd forgotten something that is very significant.

From the trial protocol -

Quote:

---

Measure immune biomarkers (PD-L1) in CTCs, metastatic tissue and immune cells such as CAMLs and correlate with therapeutic benefit (PFS)

Correlation between CCR5 expression (CTCs, CAMLs) and PD- L1 expression.[
https://clinicaltrials.gov/study/NCT03838367?...;tab=table

---

We know that maraviroc significantly reduced PD-L1 now we'll show what leronlimab can do. Merck will not be happy.

Quote:

---

"completely shut down Amarex"...seems to have happened anyway. No evidence of work ethic in several years.

---

After the debacle that was our BLA would any pharma want to work with Amarex. I'm betting NSF is throwing them some sidework so they money they spent isn't completely wasted.